<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12304">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00498628</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAA_DTRR-2007-LITTEN-01</org_study_id>
    <nct_id>NCT00498628</nct_id>
  </id_info>
  <brief_title>Study of the Effectiveness of Quetiapine for the Treatment of Alcohol Dependency</brief_title>
  <official_title>A Phase 2, Double-Blind, Placebo Controlled Trial to Assess the Efficacy of Quetiapine Fumarate Extended Release for the Treatment of Alcohol Dependence in Very Heavy Drinkers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether quetiapine fumarate extended release is
      effective in the treatment of alcohol dependence in very heavy drinkers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate quetiapine fumarate XR (SEROQUEL XR®), a dibenzothiazepine
      derivative, as a potential medication for treating alcohol dependence. The immediate release
      form of quetiapine fumarate, SEROQUEL XR®, is approved by the FDA for treatment of
      schizophrenia and acute manic episodes associated with bipolar disorder. The extended
      release formulation (SEROQUEL XR®) is also approved by the FDA and is undergoing clinical
      investigation for the treatment of major depressive disorders, schizophrenia, generalized
      anxiety disorder, and alcohol dependence.

      Treatment with other atypical antipsychotics such as clozapine and olanzapine has resulted
      in decreases in alcohol use in alcohol dependent patients with and without comorbid
      psychiatric diagnoses. Quetiapine, like clozapine, appears to have efficacy in reducing drug
      and alcohol use among alcoholics and drug dependent patients with co-morbid psychiatric
      illness.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent Heavy Drinking Days</measure>
    <time_frame>Weeks 3 - 11</time_frame>
    <safety_issue>No</safety_issue>
    <description>A heavy drinking day is defined as 5 or more drinks for men and 4 or more drinks for women during a 24 hour period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Days Abstinent</measure>
    <time_frame>3-11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drinks Per Drinking Day</measure>
    <time_frame>3-11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drinks Per Day</measure>
    <time_frame>3-11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Very Heavy Drinking Day</measure>
    <time_frame>3-11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Subjects Abstinent</measure>
    <time_frame>3-11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Subjects With no Heavy Drinking Day</measure>
    <time_frame>3-11</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drinking Consequences Score</measure>
    <time_frame>Weeks 6 and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>DrInc Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Craving Score</measure>
    <time_frame>Week 4, 6, 8, 10, 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>PACS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression Score</measure>
    <time_frame>Week 4, 6, 8, 10, and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>MADRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety Score</measure>
    <time_frame>Weeks 4, 6, 8, 10 and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>HAM-A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality Score</measure>
    <time_frame>Weeks 4, 8 and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pittsburgh Sleep Quality Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Score</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of Life SF - 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>Alcoholism</condition>
  <condition>Alcohol Abuse</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quetiapine fumarate plus medical management</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Medical management plus placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine fumarate</intervention_name>
    <description>Quetiapine fumarate- taken daily, for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>SEROQUEL XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between the ages of 18 and 65 years old

          -  DSM-IV diagnosis of current alcohol dependence as supported by SCID Module E

          -  Report &quot;very heavy&quot; drinking (10 or more drinks per drinking day for men or 8 or more
             drinks per drinking day for women) at least 40% of the days during the interval from
             day 31 to 90 prior to the initial screening visit (i.e. a total of 24 days of this
             60-day period), with at least one day of &quot;very heavy&quot; drinking occurring within the
             last 2 weeks before screening

          -  Seeking treatment for alcohol dependence and desire reduction or cessation of
             drinking

          -  Able to verbalize understanding of the consent form, able to provide written informed
             consent, and verbalize willingness to complete study procedures

          -  Females of child bearing potential must agree to use of at least one approved method
             of birth control, or must be surgically sterile or postmenopausal

          -  Able to take oral medication, willing to adhere to the medication regimen, and
             willing to return for regular visits

          -  Able to understand written and oral instructions in English and to complete the
             questionnaires required by the protocol

          -  Can complete all psychological assessments required at screening and baseline

          -  Able to provide evidence of stable residence in the last 2 months prior to
             randomization, have reasonable transportation arrangements to study site, and have no
             plans to move within the next 3 months or unresolved legal problems; must provide
             contact information of family member, spouse, or significant other who can contact
             subject in case of missed appointment

          -  Breath alcohol concentration (BAC) equal to 0.00 when s/he signed the informed
             consent document

          -  Must have an absolute neutrophil count of 1.5 x 109/L or greater.

        Exclusion Criteria:

        Please contact site for additional information.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raye Z. Litten, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margaret E. Mattson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joanne Fertig, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston University School of Medicine, Psychiatry Clinical Studies Unit</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Medical School, Dept. of Psychiatry</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Treatment Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown University Center for Alcohol and Addiction Studies</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>12906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>White River Junction VA Medical Center</name>
      <address>
        <city>White River Junction</city>
        <state>Vermont</state>
        <zip>05009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia, Dept. of Psychiatric Medicine</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, Murtaugh C, Ciraulo D, Green AI, Johnson B, Pettinati H, Swift R, Afshar M, Brunette MF, Tiouririne NA, Kampman K, Stout R; NCIG 001 Study Group. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2012 Mar;36(3):406-16. doi: 10.1111/j.1530-0277.2011.01649.x. Epub 2011 Sep 26.</citation>
    <PMID>21950727</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 17, 2015</lastchanged_date>
  <firstreceived_date>July 6, 2007</firstreceived_date>
  <firstreceived_results_date>April 25, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcoholism</keyword>
  <keyword>Alcohol dependence</keyword>
  <keyword>Quetiapine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Quetiapine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Interested candidates responded by telephone to advertisements at 5 academic centers in the United States between December 2007 and May 2009.</recruitment_details>
      <pre_assignment_details>218 comprises the Modified Intent To Treat group (MITT)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Quetiapine Fumerate Plus Medical Management</title>
          <description>Quetiapine fumarate - target dose 400mg/day plus medical management</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill Plus Medical Management</title>
          <description>Medical management plus placebo comparator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Quetiapine Fumerate Plus Medical Management</title>
          <description>Quetiapine fumarate - target dose 400mg/day plus medical management</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill Plus Medical Management</title>
          <description>Medical management plus placebo comparator</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="105"/>
                <measurement group_id="B2" value="113"/>
                <measurement group_id="B3" value="218"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="105"/>
                <measurement group_id="B2" value="113"/>
                <measurement group_id="B3" value="218"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="45.4" spread="9.3"/>
                <measurement group_id="B2" value="45.5" spread="9.8"/>
                <measurement group_id="B3" value="45.4" spread="9.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="26"/>
                <measurement group_id="B3" value="43"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="88"/>
                <measurement group_id="B2" value="87"/>
                <measurement group_id="B3" value="175"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="105"/>
                <measurement group_id="B2" value="113"/>
                <measurement group_id="B3" value="218"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Heavy Drinking Days</title>
        <description>A heavy drinking day is defined as 5 or more drinks for men and 4 or more drinks for women during a 24 hour period.</description>
        <time_frame>Weeks 3 - 11</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intention to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumerate Plus Medical Management</title>
            <description>Quetiapine fumarate - target dose 400mg/day plus medical management</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill Plus Medical Management</title>
            <description>Medical management plus placebo comparator</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                  <measurement group_id="O2" value="113"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Heavy Drinking Days</title>
            <description>A heavy drinking day is defined as 5 or more drinks for men and 4 or more drinks for women during a 24 hour period.</description>
            <units>percentage of heavy drinking days</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="37.1" spread="3.5"/>
                  <measurement group_id="O2" value="37.9" spread="3.34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Days Abstinent</title>
        <time_frame>3-11</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drinks Per Drinking Day</title>
        <time_frame>3-11</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drinks Per Day</title>
        <time_frame>3-11</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Very Heavy Drinking Day</title>
        <time_frame>3-11</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Subjects Abstinent</title>
        <time_frame>3-11</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Subjects With no Heavy Drinking Day</title>
        <time_frame>3-11</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drinking Consequences Score</title>
        <description>DrInc Score</description>
        <time_frame>Weeks 6 and 12</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Craving Score</title>
        <description>PACS</description>
        <time_frame>Week 4, 6, 8, 10, 12</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depression Score</title>
        <description>MADRS</description>
        <time_frame>Week 4, 6, 8, 10, and 12</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anxiety Score</title>
        <description>HAM-A</description>
        <time_frame>Weeks 4, 6, 8, 10 and 12</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality Score</title>
        <description>Pittsburgh Sleep Quality Index</description>
        <time_frame>Weeks 4, 8 and 12</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Score</title>
        <description>Quality of Life SF - 12</description>
        <time_frame>Week 12</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Quetiapine Fumerate Plus Medical Management</title>
          <description>Quetiapine fumarate - target dose 400mg/day plus medical management</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill Plus Medical Management</title>
          <description>Medical management plus placebo comparator</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Ruptured Spleen</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pre-ventricular contractions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Automobile Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol Detoxification</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Behavioral Disturbance while intoxicated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="36" subjects_affected="34" subjects_at_risk="105"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="14" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="105"/>
                <counts group_id="E2" events="25" subjects_affected="20" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="105"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="29" subjects_affected="22" subjects_at_risk="105"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Feeling Abnormal</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="105"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight Increased</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="105"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Appetite</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E2" events="22" subjects_affected="15" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="105"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Mylagia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="105"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="105"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Somnelence</sub_title>
                <counts group_id="E1" events="42" subjects_affected="36" subjects_at_risk="105"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="60" subjects_affected="36" subjects_at_risk="105"/>
                <counts group_id="E2" events="83" subjects_affected="49" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="105"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="26" subjects_affected="20" subjects_at_risk="105"/>
                <counts group_id="E2" events="33" subjects_affected="25" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="105"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Depressed Mood</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Abnormal Dreams</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="105"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="105"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="105"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Oropharynageal Pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="105"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Raye Litten</name_or_title>
      <organization>NIAAA</organization>
      <phone>301-443-0636</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
